Application for marketing authorisation for the use of Neupro® (rotigotine transdermal patch) in the treatment of moderate-to-severe Restless Legs Syndrome (RLS) accepted for filing by the European Medicines Agency (EMEA).
Application for marketing authorisation for the use of Neupro® (rotigotine transdermal patch) in the treatment of moderate-to-severe Restless Legs Syndrome (RLS) accepted for filing by the European Medicines Agency (EMEA).
